Literature DB >> 18417336

Cytokine-producing B lymphocytes-key regulators of immunity.

Frances E Lund1.   

Abstract

The successful use of B cell depletion therapy for the treatment of autoimmune disease has led to a resurgent appreciation of B cells as powerful regulators of immunity. However, to the surprise of many, B cells appear to regulate autoimmune conditions independently of their ability to produce autoantibodies. Indeed, disturbances in the ability of B cell subsets to present antigen, produce cytokines, and regulate the activities of T cells is emerging as a key feature in many inflammatory diseases. Here we review the recent literature describing cytokine-producing regulatory and effector B cell subsets in health and disease and discuss how future B cell-directed therapies might target the pathologic cytokine-producing effector B cell subsets without impacting the protective regulatory subsets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417336      PMCID: PMC2474694          DOI: 10.1016/j.coi.2008.03.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  53 in total

1.  Distinct profiles of human B cell effector cytokines: a role in immune regulation?

Authors:  Martin E Duddy; Andrea Alter; Amit Bar-Or
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

Review 2.  Evolving views on the genealogy of B cells.

Authors:  Robert S Welner; Rosana Pelayo; Paul W Kincade
Journal:  Nat Rev Immunol       Date:  2008-02       Impact factor: 53.106

Review 3.  Regulation of interferon-gamma production by IL-12 and IL-18.

Authors:  H Okamura; S Kashiwamura; H Tsutsui; T Yoshimoto; K Nakanishi
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

Review 4.  Production of cytokines by human B cells in health and disease.

Authors:  V Pistoia
Journal:  Immunol Today       Date:  1997-07

5.  B-cell-derived IL-10: production and function.

Authors:  N Burdin; F Rousset; J Banchereau
Journal:  Methods       Date:  1997-01       Impact factor: 3.608

6.  Intracellular demonstration of active TGFbeta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection.

Authors:  T E Caver; F X O'Sullivan; L I Gold; H D Gresham
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

7.  B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion.

Authors:  Y X Fu; G Huang; Y Wang; D D Chaplin
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

8.  The sequential role of lymphotoxin and B cells in the development of splenic follicles.

Authors:  M Gonzalez; F Mackay; J L Browning; M H Kosco-Vilbois; R J Noelle
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

9.  Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells.

Authors:  R Endres; M B Alimzhanov; T Plitz; A Fütterer; M H Kosco-Vilbois; S A Nedospasov; K Rajewsky; K Pfeffer
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

10.  Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.

Authors:  J L Schultze; S Michalak; J Lowne; A Wong; M H Gilleece; J G Gribben; L M Nadler
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  243 in total

1.  A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.

Authors:  Hiroaki Kaku; Kai Fan Cheng; Yousef Al-Abed; Thomas L Rothstein
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

3.  Indications of rituximab in autoimmune diseases.

Authors:  Iñaki Sanz
Journal:  Drug Discov Today Ther Strateg       Date:  2009-04-01

Review 4.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

5.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

6.  Ischemic transient neurological events identified by immune response to cerebral ischemia.

Authors:  Glen C Jickling; Xinhua Zhan; Boryana Stamova; Bradley P Ander; Yingfang Tian; Dazhi Liu; Shara-Mae Sison; Piero Verro; S Claiborne Johnston; Frank R Sharp
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

7.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

8.  Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.

Authors:  Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-07       Impact factor: 5.209

Review 9.  Regulatory B cells in experimental stroke.

Authors:  Hilary A Seifert; Arthur A Vandenbark; Halina Offner
Journal:  Immunology       Date:  2018-02-05       Impact factor: 7.397

10.  CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential.

Authors:  Safiehkhatoon Moshkani; Igor I Kuzin; Funmilola Adewale; Johan Jansson; Iñaki Sanz; Edward M Schwarz; Andrea Bottaro
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.